Radium-223: a new treatment option for bone-metastatic CRPC

被引：0
|
作者：
Petros D. Grivas
Evan T. Keller
机构：
[1] C353 Med Inn Building,Division of Hematology/Oncology, Department of Internal Medicine
[2] SPC 5848,Department of Urology
[3] University of Michigan,undefined
[4] Room 5308,undefined
[5] Cancer Center,undefined
[6] University of Michigan,undefined
来源：
Nature Reviews Urology | 2013年 / 10卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Radium-223 is an emitter of high-energy α particles that binds selectively to areas of high bone turnover. In a recently published phase III trial, it prolonged overall survival of patients with symptomatic, castration-resistant prostate cancer with bone metastases and, as a result, has gained FDA approval for this indication.
引用
收藏
页码：630 / 631
页数：1
相关论文
共 50 条
  • [21] Radium-223 Therapy in Metastatic Castration - Is post treatment bone scan helpful to assess treatment response ?
    Aniceto, D.
    Cruz, M. Botelho
    Nunes, A.
    Lewington, V.
    Fahim, H.
    Allen, S.
    Mills, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S143 - S143
  • [22] Utilization of Radium-223 in Metastatic Prostate Cancer Patients and Novel Prognostic Indicators In Radium-223 Patients
    Parsons, M. W.
    Tward, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E899 - E899
  • [23] Radium-223: Optimizing Treatment and Research of Osteoblastic Bone Metastasis
    Tu, Shi-Ming
    Bilen, Mehmet Asim
    Lin, Sue-Hwa
    ONCOLOGY-NEW YORK, 2015, 29 (07): : 490 - 492
  • [24] Residents' Guide to Radium-223 Dichloride Treatment For Metastatic Prostate Cancer
    Ersahin, Devrim
    Chen, Ming-Kai
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [25] Radium-223 for the treatment of prostate cancer
    Hafeez, Shaista
    Parker, Christopher
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (03) : 379 - 387
  • [26] Radium-223 In The Treatment Of Metastatic Castration-Resistant Prostate Cancer
    Vazzana, C.
    Morano, S.
    Di Lascio, A.
    Grana, C.
    Chinol, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S880 - S880
  • [27] Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome
    Cheng, Sierra
    Arciero, Vanessa
    Goldberg, Hanan
    Tajzler, Camilla
    Manganaro, Aileen
    Kozlowski, Natascha
    Rowbottom, Leigha
    McDonald, Rachel
    Chow, Ronald
    Vasisht, Gaurav
    Shaji, Sharon
    Wong, Emily Chu Lee
    Petrovic, Michele
    Zhang, Liying
    Phillips, Cameron
    Zalewski, Pawel
    Kapoor, Anil
    Fleshner, Neil E.
    Chow, Edward
    Emmenegger, Urban
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9307 - 9319
  • [28] Radium-223: Down to the Bone, and Less Is More
    Chang, Albert J.
    Roach, Mack, III
    ONCOLOGY-NEW YORK, 2012, 26 (04): : 342 - 344
  • [29] Radium-223 dichloride (Ra-223) improves survival in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets): nursing roles in implementing this new treatment (tx) option
    Causer, L.
    Johnson, B.
    Sicari, R.
    Lavent, F.
    Lien, L. M. E.
    Jensen, T.
    Wahba, M.
    Parker, C.
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2014, 18 : S21 - S21
  • [30] Radium-223 dichloride: a new paradigm in the treatment of prostate cancer
    Anido Herranz, Urbano
    Fernandez Calvo, Ovidio
    Afonso Afonso, Francisco Javier
    Martinez de Llano, Sofia Rodriguez
    Lazaro Quintela, Martin
    Leon Mateos, Luis
    Vazquez Estevez, Sergio
    Anton Aparicio, Luis Miguel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (03) : 339 - 348
12345